Amgen, Inc. (NASDAQ:AMGN) announced the U.
Amgen, Inc. (NASDAQ:AMGN) announced it will present data from its oncology portfolio and pipeline at the European Cancer Congress 2015 (ECC 2015), Sept.
Amgen, Inc. (NASDAQ:AMGN) announced the submission of an application to the U.
A number of Wall Street analysts weighed in on their favorite stocks this morning before market open. Below are the most notable analyst …
Amgen, Inc.’s (NASDAQ:AMGN) cholesterol-reducing drug, Repatha, was approved by the FDA last week, nearly a month after it was already approved by European …
Amgen, Inc. (NASDAQ:AMGN) announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for etelcalcetide …
Amgen, Inc. (NASDAQ:AMGN) announced a neuroscience collaboration with Novartis in the areas of Alzheimer’s disease and migraine.
Amgen, Inc. (NASDAQ:AMGN) and UCB announced top-line results from the STRUCTURE trial (STudy evaluating effect of RomosozUmab Compared with Teriparatide in postmenopaUsal women with …
Piper Jaffray’s healthcare analyst Joshua Schimmer weighed in with his views on Amgen, Inc. (NASDAQ:AMGN), following the news that the company received FDA approval for its PCSK9 inhibitor …
Amgen, Inc. (NASDAQ:AMGN) announced that the U.